Skip to main content

Advertisement

Log in

Amino-terminal pro-brain natriuretic peptide as a prognostic marker in patients with rheumatoid arthritis

Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Rheumatoid arthritis (RA) is associated with increased cardiovascular (CV) morbidity and mortality, of which amino-terminal pro-brain natriuretic peptide (NT-proBNP) is a predictor. The objective of the study was to investigate associations between NT-proBNP and age, gender, markers of inflammation, disease activity, and kidney function in RA patients, without co-morbidities potentially influencing NT-proBNP concentration. The study group consisted of 90 patients with RA, without clinically relevant coronary heart disease, hypertension, diabetes, advanced chronic kidney disease. The comprehensive assessment of clinical and laboratory parameters of inflammation, disease activity, and kidney function was performed. Plasma samples were frozen for NT-proBNP analysis. Carotid intima media thickness (cIMT) was determined by high-resolution B-mode ultrasonography. The mean NT-proBNP concentrations were significantly higher in a group of RA patients with high disease activity (DAS28 > 5.1) and in a group of patients with subclinical atherosclerosis diagnosed by cIMT ≥ 0.6 mm. In all RA patients, NT-proBNP correlated positively with the age, C-reactive protein, erythrocyte sedimentation rate, cIMT, tricipital skin fold and negatively with hand-grip strength, hemoglobin, red blood cell count, albumin. In the group of women with RA, we found significant positive correlation between NT-proBNP and cystatin-C. Also, patients with NT-proBNP level ≥ 100 pg/ml had significantly higher cystatin-C than those with lower NT-proBNP. NT-proBNP level, in RA patients without co-morbidities potentially influencing this level, is correlated with age, disease activity markers of inflammation, and subclinical renal impairment. It means that risk of CV disorders is higher in older patients with more active RA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Naranjo A, Sokka T, Descalzo MA et al (2008) QUEST-RA Group: cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 10:R30

    Article  PubMed  Google Scholar 

  2. Koivuniemi R, Paimela L, Leirisalo-Repo M (2009) Causes of death in patients with rheumatoid arthritis from 1971 to 1991 with special reference to autopsy. Clin Rheumatol 28:1443–1447

    Article  PubMed  Google Scholar 

  3. Gabriel SE (2008) Cardiovascular morbidity and mortality in rheumatoid arthritis. Am J Med 121:S9–S14

    Article  PubMed  Google Scholar 

  4. Maradit-Kremers H, Crowson CS, Nicola PJ et al (2005) Increased unrecognized coronary heart disease and sudden death in rheumatoid arthritis. Arthritis Rheum 52:402–411

    Article  PubMed  Google Scholar 

  5. Holly J, Kitas G, Toms T, Goodson N (2009) Cardiovascular co-morbidity in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 23:71–82

    Article  Google Scholar 

  6. Dessein PH, Norton GR, Woodiwiss AJ et al (2007) Influence of nonclassical cardiovascular risk factors on the accuracy of predicting subclinical atherosclerosis in rheumatoid arthritis. J Rheumatol 34:943–951

    PubMed  Google Scholar 

  7. Gonzalez-Gay MA, Gonzalez-Juanatey C, Piñeiro A et al (2005) High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. J Rheumatol 32:1219–1223

    CAS  PubMed  Google Scholar 

  8. Nishikimi T, Maeda N, Matsuoka H (2006) The role of natriuretic peptides in cardioprotection. Cardiovasc Res 69:318–328

    Article  CAS  PubMed  Google Scholar 

  9. Felker GM, Petersen JW, Mark DB (2006) Natriuretic peptides in the diagnosis and management of heart failure. CMAJ 175:611–617

    PubMed  Google Scholar 

  10. Wang TJ, Larson MG, Levy D et al (2004) Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Eng J Med 350:655–663

    Article  CAS  Google Scholar 

  11. Olsen MH, Hansen TW, Christensen MK et al (2007) N-terminal pro-brain natruretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population. Eur Heart J 28:1374–1381

    Article  CAS  PubMed  Google Scholar 

  12. Tsuchida K, Tanabe K (2008) Plasma brain natriuretic peptide concentrations and the risk of cardiovascular events and death in general practice. J Cardiol 52:212–223

    Article  PubMed  Google Scholar 

  13. Linssen GC, Bakker SJ, Voors AA et al (2010) N-terminal pro-B-type natriuretic peptide is an independent predictor of cardiovascular morbidity and mortality in the general population. Eur Heart J 31:120–127

    Article  CAS  PubMed  Google Scholar 

  14. Korngold EC, Januzzi JL Jr, Gantzer ML et al (2009) Amino-terminal pro-B-type natriuretic peptide and high-sensitivity C-reactive protein as predictors of sudden cardiac death among women. Circulation 119:2868–2876

    Article  CAS  PubMed  Google Scholar 

  15. Barbato E, Rubattu S, Bartunek J et al (2009) Human coronary atherosclerosis modulates cardiac natriuretic peptide release. Atherosclerosis 206:258–264

    Article  CAS  PubMed  Google Scholar 

  16. Solus J, Chung CP, Oeser A et al (2008) Amino-terminal fragment of the prohormone brain-type natriuretic peptide in rheumatoid arthritis. Arthritis Rheum 58:2662–2669

    Article  PubMed  Google Scholar 

  17. Provan SA, Angel K, Ødegard S et al (2008) The association between disease activity and NT-proBNP in 238 patients with rheumatoid arthritis: a 10-year longitudinal study. Arthritis Res Ther 10:R70

    Article  PubMed  Google Scholar 

  18. Harney SMJ, Timperley J, Daly C et al (2007) Brain natriuretic peptide is a potentially useful screening tool for the detection of cardiovascular disease in patients with rheumatoid arthritis. Ann Rheum Dis 65:136

    Article  Google Scholar 

  19. Karadag O, Calguneri M, Yavuz B et al (2007) B-type natriuretic peptide (BNP) levels in female systemic lupus erythematosus patients: what is the clinical significance? Clin Rheumatol 26:1701–1704

    Article  PubMed  Google Scholar 

  20. Provan S, Angel K, Semb AG et al (2010) NT-proBNP predicts mortality in patients with rheumatoid arthritis: results from 10-year follow-up of the EURIDISS study. Ann Rheum Dis. doi:10.1136/ard.2009.127704

    Google Scholar 

  21. Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324

    Article  CAS  PubMed  Google Scholar 

  22. Prevoo ML, vant’t Hof MA, Kuper HH et al (1995) Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48

    Article  CAS  PubMed  Google Scholar 

  23. Pincus T, Sokka T, Kautiainen H (2005) Further development of a physical function scale on a MDHAQ [corrected] for standard care of patients with rheumatic diseases. J Rheumatol 32:1432–1439

    PubMed  Google Scholar 

  24. Cockroft DW, Gault MH (1976) Preddiction of creatinine clearance from serum creatinine. Nephron 16:31–41

    Article  Google Scholar 

  25. Levey AS, Bosch JP, Lewis JB et al (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 130:461–470

    CAS  PubMed  Google Scholar 

  26. Shlipak MG, Katz R, Sarnak MJ et al (2006) Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 145:237–247

    CAS  PubMed  Google Scholar 

  27. Brune K, Katus HA, Moecks J et al (2008) N-terminal pro-B-type natriuretic peptide concentrations predict the risk of cardiovascular adverse events form anti-inflammatory drugs: a pilot study. Clin Chem 54:1149–1157

    Article  CAS  PubMed  Google Scholar 

  28. Poredos P (2004) Intima-media thickness: indicator of cardiovascular risk and measure of the extent of atherosclerosis. Vasc Med 9:46–54

    Article  PubMed  Google Scholar 

  29. Gonzalez-Juanatey C, Llorca J, Martin J, Gonzalez-Gay MA (2009) Carotid intima-media thickness predicts the development of cardiovascular events in patients with rheumatoid arthritis. Semin Arthritis Rheum 38:366–371

    Article  PubMed  Google Scholar 

  30. Veller MG, Fisher CM, Nicolaides AN et al (1993) Measurement of the ultrasonic intima-media complex thickness in normal subjects. J Vasc Surg 17:719–725

    Article  CAS  PubMed  Google Scholar 

  31. Steinbrocker O, Treger H, Cornelius H (1949) Therapeutic criteria in rheumatoid arthritis. JAMA 140:659–662

    CAS  Google Scholar 

  32. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection and treatment of high blood cholesterol in adults (Adult treatment Pannel III). JAMA 285:2468–2497

    Article  Google Scholar 

  33. Peters MJL, Welsh P, McInnea IB et al (2010) TNFα blockade therapy reduces circulating NT-proBNP levels in RA patients with active disease: results from prospective cohort study. Ann Rheum Dis 69:1281–1285

    Article  CAS  PubMed  Google Scholar 

  34. Belcaro G, Nicolaides AN, Ramaswami G et al (2001) Carotid and femoral ultrasound morphology screening and cardiovascular events in low risk subjects: a 10-year follow-up study (the CAFES-CAVE study). Atherosclerosis 156:379–387

    Article  CAS  PubMed  Google Scholar 

  35. Gonzalez-Gay MA, Gonzalez-Juanatey C, Vazquez-Rodriguez TR et al (2008) Endothelial dysfunction, carotid intima-media thickness, and accelerated atherosclerosis in rheumatoid arthritis. Semin Arthritis Rheum 38:67–70

    Article  PubMed  Google Scholar 

  36. Crilly MA, Clark HJ, Kumar V et al (2010) Relationship between arterial stiffness and Stanford Health Assessment Questionnaire disability in rheumatoid arthritis patients without overt arterial disease. J Rheumatol 37:946–952

    Article  PubMed  Google Scholar 

  37. Linzbach S, Samigullin A, Yilmaz S et al (2009) Role of N-terminal pro-brain natriuretic peptide and cystatin C to estimate renal function in patients with and without heart failure. Am J Cardiol 103:1128–1133

    Article  CAS  PubMed  Google Scholar 

  38. DeFilippi CR, Fink JC, Nass CM et al (2005) N-terminal pro-B-type natriuretic peptide for predicting coronary disease and left ventricular hypertrophy in asymptomatic CKD not requiring dialysis. Am J Kidney Dis 46:35–44

    Article  CAS  PubMed  Google Scholar 

  39. Luchner A, Hengstenberg C, Löwel H et al (2005) Effect of compensated renal dysfunction on approved heart failure markers: direct comparison of brain natriuretic peptide (BNP) and N-Terminal Pro-BNP. Hypertension 46:118–123

    Article  CAS  PubMed  Google Scholar 

  40. Matsumoto M, Tsujino T, Naito Y et al (2008) Anemia as a factor that elevates plasma brain natriuretic peptide concentration in apparently healthy subjects. Int Heart J 49:577–586

    Article  CAS  PubMed  Google Scholar 

  41. Desai AS, Bibbins-Domingo K, Shlipak MG et al (2007) Association between anaemia and N-terminal pro-B-type natriuretic peptide (NT-proBNP): findings from the heart and soul study. Eur J Heart Fail 9:886–891

    Article  CAS  PubMed  Google Scholar 

  42. Gómez-Vaquero C, Nolla JM, Fiter J et al (2001) Nutritional status in patients with rheumatoid arthritis. Joint Bone Spine 68:403–409

    Article  PubMed  Google Scholar 

  43. Heimbürger O, Qureshi AR, Blaner WS et al (2000) Hand-grip muscle strength, lean body mass, and plasma proteins as markers of nutritional status in patients with chronic renal failure close to start of dialysis therapy. Am J Kidney Dis 36:1213–1225

    Article  PubMed  Google Scholar 

  44. Guo Q, Bárány P, Qureshi AR et al (2009) N-terminal pro-brain natriuretic peptide independently predicts protein energy wasting and is associated with all-cause mortality in prevalent HD patients. Am J Nephrol 29:516–523

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We would like to thank Prof. Małgorzata Szczerbo-Trojanowska and Dr Anna Drelich-Zbroja (Department of Interventional Radiology and Neuroradiology, Medical University, Lublin) for the successful cooperation when assessing cIMT. We would like also to thank Prof. Andrzej Krajka (Maria Curie-Sklodowska University of Lublin) for his help with statistical analyses of data.

Disclosures

None

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Bożena Targońska-Stępniak.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Targońska-Stępniak, B., Majdan, M. Amino-terminal pro-brain natriuretic peptide as a prognostic marker in patients with rheumatoid arthritis. Clin Rheumatol 30, 61–69 (2011). https://doi.org/10.1007/s10067-010-1622-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-010-1622-0

Keywords

Navigation